Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics reported first quarter 2026 results and highlighted major clinical progress for its lead PI3Kα inhibitor zovegalisib.
Revenue was $3.0 million for Q1 2026 versus $7.7 million a year earlier, while R&D expenses were $70.6 million and G&A expenses $11.0 million. Net loss narrowed to $73.3 million, or $0.41 per share, compared with a net loss of $77.1 million, or $0.46 per share, in Q1 2025.
Cash, cash equivalents and investments rose to $642.1 million as of March 31, 2026, helped by $137.1 million in at-the-market equity proceeds, and are expected to fund operations into 2029. Strategically, zovegalisib received FDA Breakthrough Therapy designation in advanced HR+/HER2- breast cancer, showed 11.1‑month median progression-free survival in a Phase 1/2 trial, and delivered a 44% objective response rate in a triplet regimen in heavily pre-treated patients. The company also initiated a Phase 1/2 trial for RLY‑8161, an NRAS-selective inhibitor, and plans a Phase 3 frontline breast cancer study in early 2027.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo had 972 shares of common stock sold on April 28, 2026 at $14.79 per share. According to the disclosure, this transaction was executed to cover his income tax withholding obligations from the vesting of 3,268 restricted stock units on April 27, 2026 and he had no discretion over the sale, which followed company policies.
After this tax-related sale, Catinazzo beneficially owned 212,895 shares of Relay Therapeutics common stock, including 9,807 shares underlying restricted stock units.
Relay Therapeutics, Inc. executive Peter Rahmer reported an open-market sale of 753 shares of common stock at $14.79 per share. According to the footnotes, the sale was made solely to cover income tax withholding on the vesting of 3,051 restricted stock units and was not discretionary. After this transaction, Rahmer directly owns 275,857 shares of Relay Therapeutics common stock, including 9,153 shares underlying RSUs, indicating the sale was small relative to his overall position.
Relay Therapeutics, Inc. President of R&D Donald A. Bergstrom reported a small, tax-related share sale. On April 28, 2026, he sold 1,490 shares of common stock at $14.79 per share. A footnote explains the sale covered income tax withholding on 5,012 RSUs that vested on April 27, 2026 and that he had no discretion over the transaction, which followed company policies for RSU vesting. After this sale, he directly holds 418,557 shares, including 15,037 shares underlying RSUs.
Relay Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026. Key items include electing two Class III directors, an advisory approval of named executive officer pay, and ratifying Ernst & Young LLP as independent auditor for 2026.
The board is also seeking approval to amend the certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares. Stockholders of record as of April 13, 2026 may vote online, by phone, by mail, or during the webcast. The board recommends voting "FOR" all four proposals.
Relay Therapeutics reported early clinical data for its PI3Kα inhibitor zovegalisib in a triplet regimen with atirmociclib and fulvestrant in heavily pre‑treated HR+/HER2‑ metastatic breast cancer. Among 34 patients with measurable disease, the objective response rate was 44% (15/34), similar in kinase and non‑kinase PIK3CA mutations, and 85% showed tumor shrinkage.
Safety in 62 treated patients appeared manageable: only 3% discontinued and 10% dose‑reduced zovegalisib for treatment‑related adverse events, with a 40% grade 3+ TRAE rate primarily due to neutropenia and no febrile neutropenia. As of the April 13, 2026 data cut‑off, 77% (48/62) of patients remained on study with a median follow‑up of 7.4 months, and median progression‑free survival has not yet been reached.
Based on these data, Relay plans, subject to regulatory feedback, a randomized Phase 3 frontline trial in endocrine‑sensitive, PIK3CA‑mutated HR+/HER2‑ advanced or metastatic breast cancer, testing zovegalisib plus atirmociclib and an aromatase inhibitor versus an investigator’s‑choice CDK4/6 inhibitor plus aromatase inhibitor. Pfizer will supply atirmociclib and palbociclib, while Relay sponsors and funds the trial.
Relay Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held virtually on June 9, 2026 at 3:00 p.m. Eastern Time. The meeting agenda includes election of two Class III directors, an advisory vote on executive compensation, ratification of Ernst & Young LLP as auditor, and a proposal to amend the certificate of incorporation to increase authorized common shares from 300,000,000 to 450,000,000.
Stockholders of record as of April 13, 2026 may vote; proxy materials and the 2025 Annual Report will be made available starting on or about April 29, 2026. The board recommends a vote FOR all proposals. Registration for the virtual meeting is required by June 5, 2026 at 5:00 p.m. ET via www.proxydocs.com/RLAY.
Kiora Pharmaceuticals reported that Perceptive Life Sciences Master Fund, Ltd. directly holds 438,471 shares of Common Stock, representing 9.99% of the class. Perceptive Advisors LLC and Joseph Edelman are each reported as beneficial owners of the same 438,471 shares (9.99%) through shared voting and dispositive power. The filing ties the outstanding share base to 4,389,099 shares, comprised of 3,950,628 shares outstanding as of March 21, 2026 and 438,471 shares issued in a private placement on April 6, 2026.